Updated:
Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other...
Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
General information
Firm type
Asset Manager
Year founded
1923
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Bagsvaerd
Corporate office
Bagsvaerd, Denmark
Principals
Lars Fruergaard Jørgensen
President and Chief Executive Officer
Sector focus
Frequently asked questions
How does the Novo Nordisk Foundation's ownership structure affect governance?
The Novo Nordisk Foundation holds a majority of voting shares through a dual-class equity setup. This structure concentrates decision-making power to prioritize long-term research, insulating the firm's management from short-term market demands. It is a deliberate architecture meant to defend multi-decade scientific investments.
Does Novo Nordisk deploy capital into external funds or direct investments?
No. Novo Nordisk's capital deployment is almost entirely internal, funding its own drug development programs and manufacturing capacity. The firm is an operating pharmaceutical company, not an investment manager that participates in fund commitments or co-investments with external GPs.
Which therapeutic areas does Novo Nordisk explicitly avoid?
Novo Nordisk does not maintain a diversified platform across oncology or infectious disease. Its explicit focus remains on diabetes, obesity, and contiguous metabolic and cardiovascular conditions. It has not announced strategies to expand into unrelated therapeutic areas.
What is the relationship between Novo Nordisk A/S and the Novo Nordisk Foundation?
The Novo Nordisk Foundation is the controlling shareholder of Novo Nordisk A/S. It channels dividends and share returns into large-scale philanthropic contributions, primarily in scientific research and societal initiatives. The firm's profits and the foundation's grantmaking are inextricably linked.
What is Novo Nordisk's posture on co-investments alongside external GPs?
As an operating company, Novo Nordisk does not have a posture on GP co-investments. It does not run a fund-of-funds program, nor does it allocate to private equity or venture capital strategies through a typical family-office or institutional-investor framework.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: